29. Takhzyro

shire
Patients only have to take Shire’s drug once or twice a month, compared with twice a week for Haegarda. (Shire)

Active ingredient: lanadelumab-flyo 
Disease: hereditary angioedema 
Peak sales estimate: $1.8 billion 
Approved: Aug. 23 
Company: Shire 

The scoop: Shire isn’t planning on handing over its leadership position in the hereditary angioedema market any time soon, especially now that Takhzyro has hit the scene. Analysts have said the drug—which has shown it can cut down the incidence of HAE attacks by as much as 87%—could become “best-in-class.”

That’s not to say that its main competition, CSL’s Haegarda, hasn’t also put up stellar efficacy numbers. But patients only have to take Shire’s drug once or twice a month, compared with twice a week for Haegarda. So far, Takhzyro has gotten off to a flying start, raking in $51 million in third-quarter sales after an August approval. That top-line contribution helped Shire’s third-quarter immunology revenues swell to $1.2 billion. — Carly Helfand

29. Takhzyro
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.